Key Points
- CEO James Mackin sold 70,000 Artivion shares at an average price of $28.95, generating approximately $2.03 million. His remaining stake fell 7.39% to 877,275 shares.
- Artivion reported quarterly revenue of $125.76 million, exceeding the $119.99 million consensus estimate, and posted adjusted EPS of $0.13. The company had a negative net margin of 0.67% and analysts expect $0.45 in full-year EPS.
- Analyst sentiment remains broadly positive, with seven Buy ratings and one Sell rating, a “Moderate Buy” consensus, and an average price target of $44.83 versus the stock’s $27.97 opening price.
Artivion, Inc. (NYSE:AORT - Get Free Report) CEO James Mackin sold 70,000 shares of Artivion stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares of the company's stock, valued at $25,397,111.25. This trade represents a 7.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Artivion Price Performance
Shares of AORT opened at $27.97 on Friday. The company has a market cap of $1.36 billion, a P/E ratio of -399.51 and a beta of 1.25. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The firm's 50 day moving average price is $24.92 and its 200 day moving average price is $30.15.
Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. On average, research analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently commented on AORT shares. Canaccord Genuity Group boosted their target price on Artivion from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Tuesday. Wall Street Zen lowered Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Citigroup reiterated a "market outperform" rating on shares of Artivion in a research note on Tuesday, July 21st. Citizens Jmp lowered their price objective on Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research report on Friday, May 8th. Finally, Stifel Nicolaus set a $45.00 target price on shares of Artivion in a research note on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $44.83.
View Our Latest Stock Report on AORT
Institutional Investors Weigh In On Artivion
Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth $27,000. Rockefeller Capital Management L.P. raised its stake in Artivion by 150.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock valued at $30,000 after buying an additional 399 shares in the last quarter. Larson Financial Group LLC raised its stake in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock valued at $43,000 after buying an additional 563 shares in the last quarter. KBC Group NV purchased a new stake in Artivion during the 4th quarter worth about $65,000. Finally, First Horizon Corp lifted its holdings in Artivion by 199.4% during the 4th quarter. First Horizon Corp now owns 1,602 shares of the company's stock worth $73,000 after buying an additional 1,067 shares during the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.
About Artivion
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
